Novartis and Stem Cells
February 2009. What value does Novartis attach to its stem cell patents? Mark Fishman, President of the Novartis Institutes for BioMedical Research comments his company’s strategy and technology acquisitions in the field.Reading time: 1 min
Read Now: |
Other articles recommended
B2Bioworld offers you background information
Stem Cells – Failings and Deliveries
Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan K. C. Knowles, at the time Head of Roche Group Research - open access
Thinking Further About Stem Cells - Viewed from Systems Biology
Leroy Hood, President Institute for Systems Biology, Seattle, Washington (US)